<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056223</url>
  </required_header>
  <id_info>
    <org_study_id>PARIDA 01/2013</org_study_id>
    <secondary_id>2013-004955-19</secondary_id>
    <nct_id>NCT02056223</nct_id>
  </id_info>
  <brief_title>Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.</brief_title>
  <acronym>PARIDA</acronym>
  <official_title>Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padua</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current pharmacological options to treat an hemodynamically significant PDA (HsPDA) in
      preterm infants are limited to non-selective cyclo-oxygenase (COX) inhibitors, indomethacin
      or ibuprofen. Recently paracetamol exposure has been reported to successful closure of PDA.
      Aim of this randomized double-blind controlled study is to compare the efficacy and the
      safety of standard PDA treatment ibuprofen versus paracetamol-experimental treatment . We
      hypothesize that paracetamol is more effective than ibuprofen in closing PDA, perhaps
      ameliorating the safety profile of the pharmacological treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial is to compare the efficacy and safety of 2 therapeutic regimens
      for PDA treatment in a population of preterm newborns of gestational age (GA) &lt;31+6 weeks
      with respiratory distress syndrome (RDS) and HsPDA:

        -  Group A: experimental boluses of paracetamol at 15 mg/Kg four time a day for three
           consecutive days.

        -  Group B: standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three
           consecutive days.

      The primary objective of the study is: to evaluate the efficacy of paracetamol versus
      standard ibuprofen regimen, by comparing the rate of ductal closure after the first and
      second course of pharmacological treatment. (PDA diagnosed by ECHO criteria)

      The secondary objective of the study is: to evaluate the safety of the above 2 therapeutic
      regimens in term of incidence of transient renal impairment, intraventricular hemorrhage
      (IVH) or other bleeding disorders, necrotizing enterocolitis (NEC) and isolated bowel
      perforation (without signs of NEC), incidence of sign of liver toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PDA pharmacological closure</measure>
    <time_frame>Partecipants will be evaluated at the end of first and second course, at an expected avarage of 8 days of life (DOL)</time_frame>
    <description>The rate of ductal closure after the first and second course of pharmacological treatment. (PDA diagnosed by ECHO criteria) in paracetamol versus ibuprofen group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oliguria</measure>
    <time_frame>In the first 14 days of life</time_frame>
    <description>Rate of oliguria defined as a reduction on urine output less than 1ml/Kg/h,</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Necrotizing enterocolitis (NEC)</measure>
    <time_frame>In the first 14 days of life</time_frame>
    <description>Rate of NEC in the paracetamol and ibuprofen group</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraventricular haemorrhage (IVH) or death</measure>
    <time_frame>Within 28 days of life</time_frame>
    <description>Rate of intraventricular haemorrhage (IVH) or death within 28 days of life (composite outcome).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ductus Arteriosus Patent</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous paracetamol</intervention_name>
    <description>15 mg/Kg every 6 hours for three days</description>
    <arm_group_label>paracetamol</arm_group_label>
    <other_name>Paracetamol i.v.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ibuprofen</intervention_name>
    <description>10 -5-5 mg/Kg once a day for three days</description>
    <arm_group_label>Intravenous ibuprofen</arm_group_label>
    <other_name>Pedea i.v.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inborn neonates

          -  preterm neonates â‰¤ 31+ 6 days weeks gestation

          -  newborns with HsPDA

          -  parental written informed consent for participation in the study must be obtained

        Exclusion Criteria:

          -  Serum creatinine concentration greater than 1,5 mg/dl (132MMole/L)

          -  Urine output less than 1 ml/Kg/h

          -  Severe IVH (&gt; grade II according to Volpe classification)

          -  Clinical bleeding tendency (as revealed by hematuria, blood in the gastric aspirate or
             in the stools, blood in the endotracheal tube aspirate)

          -  Necrotizing enterocolitis or marked abdominal distention with gastric bile residuals

          -  Thrombocyte count of less than 50.000/mm3

          -  Proved Sepsis

          -  Severe coagulopathy or liver failure

          -  Evidence of severe birth asphyxia, that is an APGAR score below 5 at 5 minutes of age
             and/or umbilical arterial pH &lt; 7.0

          -  Known genetic or chromosomal disorders

          -  Participation in another clinical trial of any placebo, drug, biological, or device
             conducted under the provisions of a protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Lago, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's and Children's Health Department- AO- University of Padua</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Lago, MD</last_name>
    <phone>0039 049 821</phone>
    <phone_ext>3545</phone_ext>
    <email>paolalago9@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina Salvadori, MD</last_name>
    <phone>0039 049 821</phone>
    <phone_ext>3546</phone_ext>
    <email>sabrina.salvadori@sanita.padova.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NICU, Women's and Children's Health Department, Azienda Ospedaliera-University of Padua</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Lago, MD</last_name>
      <phone>0039 049 821</phone>
      <phone_ext>3545</phone_ext>
      <email>paola.lago@aopd.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Salvadori, MD</last_name>
      <phone>0039 049 821</phone>
      <phone_ext>3546</phone_ext>
      <email>sabrina.salvadori@aopd.veneto.it</email>
    </contact_backup>
    <investigator>
      <last_name>Paola Lago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina Salvadori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Chiara Frigo, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Padrini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Nardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenio Baraldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103(3):166-9. doi: 10.1159/000345337. Epub 2012 Dec 19.</citation>
    <PMID>23258386</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011 Dec;128(6):e1618-21. doi: 10.1542/peds.2011-0359. Epub 2011 Nov 7.</citation>
    <PMID>22065264</PMID>
  </results_reference>
  <results_reference>
    <citation>Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013 Jan;98(1):F94. doi: 10.1136/archdischild-2012-302044. Epub 2012 May 18.</citation>
    <PMID>22611117</PMID>
  </results_reference>
  <results_reference>
    <citation>Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child. 2011 Jun;96(6):575-80. doi: 10.1136/adc.2010.204552. Epub 2011 Feb 13.</citation>
    <PMID>21317433</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padua</investigator_affiliation>
    <investigator_full_name>Paola Lago</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Patent ductus arteriosus</keyword>
  <keyword>Preterm infant</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Ibuprofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

